LBA43 Updated response data and analysis of progression free survival by mechanism of mismatch repair loss in endometrial cancer (EC) patients (pts) treated with pembrolizumab plus carboplatin/paclitaxel (CP) as compared to CP plus placebo (PBO) in the NRG GY018 trial

Publication | Open Access

DOI Full Paper Access

Citations

References

2023

Year

Ramez N. Eskander, Michael W. Sill, Austin Miller, Lucas R. Beffa, Richard G. Moore, Joanie Mayer Hope, Fernanda Musa, Robert S. Mannel, Mark S. Shahin, G. Canturia,

Annals of Oncology

Nrg Gy018 TrialMedicineGynecologyImmune Checkpoint InhibitorProgression Free SurvivalCancer TreatmentEndometrial CancerOncologyRadiation OncologyGynecology OncologyCancer Research